What are the best routes to effectively model human colorectal cancer?

Molecular Oncology

Volumn 7, Issue 2, 2013, Pages 178-189

  Young, Madeleine ^a   Ordonez, Liliana ^a   Clarke, Alan R ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Colorectal cancer; Genetic modification; Mouse models

Indexed keywords

CELECOXIB; CURCUMIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DASATINIB; EPHRIN RECEPTOR B2; EPHRIN RECEPTOR B3; EPHRIN RECEPTOR B4; METHYL CPG BINDING PROTEIN 2; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN P27; SMAD2 PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CANCER CELL; CANCER GROWTH; COLORECTAL CANCER; DISEASE MODEL; DRUG EFFECT; GENETIC MODEL; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR XENOGRAFT;

EID: 84875813640     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.02.006     Document Type: Review

References (76)

1. Akavia U.D., Litvin O., et al. An integrated approach to uncover drivers of cancer. Cell 2010, 143(6):1005-1017.
2. Albuquerque C., Breukel C., et al. The 'just-right' signaling model: APC somatic mutations are selected based on a specific level of activation of the β-catenin signaling cascade. Human Molecular Genetics 2002, 11(13):1549-1560.
3. Andreu P., Colnot S., et al. Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. Development 2005, 132(6):1443-1451.
4. Anwar S., Hall C., et al. Hereditary non-polyposis colorectal cancer: an updated review. European Journal of Surgical Oncology 2000, 26(7):635-645.
5. Barker N., Van Es J.H., et al. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 2007, 449(7165):1003-1007.
6. Barker N., Ridgway R.A., et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2008, 457(7229):608-611.
7. Batlle E., Bacani J., et al. EphB receptor activity suppresses colorectal cancer progression. Nature 2005, 435(7045):1126-1130.
8. Bellam N., Pasche B. TGF-β signaling alterations and colon cancer. Cancer Genetics 2010, 155:85-103.
9. Bos J.L., Fearon E.R., et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987, 327(6120):293-297.
10. Casorelli I., Pannellini T., et al. The Mutyh base excision repair gene influences the inflammatory response in a mouse model of ulcerative colitis. PLoS One 2010, 5(8):e12070.
11. Cho N.L., Javid S.H., et al. Estrogen receptors α and β are inhibitory modifiers of Apc-dependent tumorigenesis in the proximal colon of Min/+ mice. Cancer Research 2007, 67(5):2366-2372.
12. Chulada P.C., Thompson M.B., et al. Genetic disruption of Ptgs-1, as well as of Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Research 2000, 60(17):4705-4708.
13. Clarke A.R., Cummings M.C., et al. Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 1995, 11(9):1913-1920.
14. Corpet D. Chemoprevention Database Colorectal Cancer Prevention 2012, Retrieved 1/12/2012, 2012.
15. Dopeso H., Mateo-Lozano S., et al. The receptor tyrosine kinase EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Research 2009, 69(18):7430-7438.
16. Edelmann W., Yang K., et al. Tumorigenesis in Mlh1 and Mlh1/Apc1638N mutant mice. Cancer Research 1999, 59(6):1301-1307.
17. El Marjou F., Janssen K.P., et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis 2004, 39(3):186-193.
18. Esteller M., Gonzalez S., et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology 2001, 19(2):299-304.
19. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990, 61(5):759-767.
20. Fodde R., Edelmann W., et al. A targeted chain-termination mutation in the mouse Apc gene results in multiple intestinal tumors. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(19):8969-8973.
21. Gryfe R., Bapat B., et al. Molecular biology of colorectal cancer. Current Problems in Cancer 1997, 21(5):233-299.
22. Hackl C., Man S., et al. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2012, 65(2):259-271.
23. S mice. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(8):2868-2873.
24. Hamamoto T., Beppu H., et al. Compound disruption of Smad2 accelerates malignant progression of intestinal tumors in Apc knockout mice. Cancer Research 2002, 62(20):5955-5961.
25. Harada N., Tamai Y., et al. Intestinal polyposis in mice with a dominant stable mutation of the β-catenin gene. The EMBO Journal 1999, 18(21):5931-5942.
26. Harman F.S., Nicol C.J., et al. Peroxisome proliferator-activated receptor-δ attenuates colon carcinogenesis. Nature Medicine 2004, 10(5):481-483.
27. Hinoi T., Akyol A., et al. Mouse model of colonic adenoma-carcinoma progression based on somatic Apc inactivation. Cancer Research 2007, 67(20):9721-9730.
28. Hung K.E., Maricevich M.A., et al. Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proceedings of the National Academy of Sciences of the United States of America 2010, 107(4):1565-1570.
29. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Research 1996, 56(4):710-714.
30. Jacoby R.F., Seibert K., et al. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Research 2000, 60(18):5040-5044.
31. Jang K.S., Song Y.S., et al. Clinicopathological significance of nuclear PTEN expression in colorectal adenocarcinoma. Histopathology 2010, 56(2):229-239.
32. 1638N mice define the roles of MSH3 and MSH6 in DNA repair and intestinal tumorigenesis. Cancer Research 2001, 61(21):7934-7942.
33. Min/+ on mouse chromosome 18. Genetics 2007, 176(2):1237-1244.
34. Li X.H., Zheng H.C., et al. PTEN expression and mutation in colorectal carcinomas. Oncology Reports 2009, 22(4):757-764.
35. March H.N., Rust A.G., et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nature Genetics 2011, 43:1202-1209.
36. Marsh V., Winton D.J., et al. Epithelial Pten is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nature Genetics 2008, 40(12):1436-1444.
37. Millar C.B., Guy J., et al. Enhanced CpG mutability and tumorigenesis in MBD4-deficient mice. Science 2002, 297(5580):403-405.
38. Miyazono K. Transforming growth factor-beta. signaling in epithelial-mesenchymal transition and progression of cancer. Proceedings of the Japan Academy. Series B, Physical and Biological Sciences 2009, 85(8):314-323.
39. Moser A., Pitot H., et al. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science (New York, NY) 1990, 247(4940):322-324.
40. Moser A.R., Dove W.F., et al. The Min (multiple intestinal neoplasia) mutation: its effect on gut epithelial cell differentiation and interaction with a modifier system. The Journal of Cell Biology 1992, 116(6):1517-1526.
41. Min: a mouse model for intestinal and mammary tumorigenesis. European Journal of Cancer 1995, 31(7):1061-1064.
42. Muñoz N.M., Upton M., et al. Transforming growth factor β receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation. Cancer Research 2006, 66(20):9837-9844.
43. Nautiyal J., Banerjee S., et al. Curcumin enhances dasatinib-induced inhibition of growth and transformation of colon cancer cells. International Journal of Cancer 2010, 128(4):951-961.
44. O'Brien C.A., Pollett A., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2006, 445(7123):106-110.
45. Min-induced intestinal tumorigenesis. Carcinogenesis 2009, 30(9):1591-1596.
46. Min mouse: down-regulation of β-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 2003, 24(2):263-267.
47. Oshima M., Oshima H., et al. Loss of Apc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated Apc gene. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(10):4482-4486.
48. Oshima M., Dinchuk J.E., et al. Suppression of intestinal polyposis in Apc(Delta 716) knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87(5):803-809.
49. + cancer stem cells with metastatic capacity in human colorectal cancer. Cell Stem Cell 2010, 6(6):603-615.
50. Parsons D., Wang T., et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005, 436(7052):792.
51. Perreault N., Sackett S.D., et al. Foxl1 is a mesenchymal Modifier of Min in carcinogenesis of stomach and colon. Science Signalling 2005, 19(3):311-315.
52. Petrova T.V., Nykänen A., et al. Transcription factor PROX1 induces colon cancer progression by promoting the transition from benign to highly dysplastic phenotype. Cancer Cell 2008, 13(5):407-419.
53. Phesse T.J., Parry L., et al. Deficiency of Mbd2 attenuates Wnt signaling. Molecular and Cellular Biology 2008, 28(19):6094-6103.
54. Philipp-Staheli J., Kim K.H., et al. Pathway-specific tumor suppression: reduction of p27 accelerates gastrointestinal tumorigenesis in Apc mutant mice, but not in Smad3 mutant mice. Cancer Cell 2002, 1(4):355-368.
55. Prolla T.A., Baker S.M., et al. Tumour susceptibility and spontaneous mutation in mice deficient in Mlh1, Pms1 and Pms2 DMA mismatch repair. Nature Genetics 1998, 18(3):276-279.
56. Quesada C.F., Kimata H., et al. Piroxicam and acarbose as chemopreventive agents for spontaneous intestinal adenomas in Apc gene 1309 knockout mice. Cancer Science 1998, 89(4):392-396.
57. Reed K.R., Sansom O.J., et al. PPARδ status and Apc-mediated tumourigenesis in the mouse intestine. Oncogene 2004, 23(55):8992-8996.
58. Reitmair A.H., Cai J.C., et al. MSH2 deficiency contributes to accelerated Apc-mediated intestinal tumorigenesis. Cancer Research 1996, 56(13):2922-2926.
59. Romagnolo B., Berrebi D., et al. Intestinal dysplasia and adenoma in transgenic mice after overexpression of an activated β-catenin. Cancer Research 1999, 59(16):3875-3879.
60. Sansom O., Reed K., et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes & Development 2004, 18(12):1385-1390.
61. Sansom O.J., Meniel V., et al. Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(38):14122-14127.
62. Sansom O.J., Meniel V.S., et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007, 446(7136):676-679.
63. Sato T., Vries R.G., et al. Single Lgr5 stem cells build crypt villus structures in vitro without a mesenchymal niche. Nature 2009, 459(7244):262-265.
64. Shibata H., Toyama K., et al. Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 1997, 278(5335):120-123.
65. Silverman K.A., Koratkar R., et al. Identification of the modifier of Min 2 (Mom2) locus, a new mutation that influences Apc-induced intestinal neoplasia. Genome Research 2002, 12(1):88-97.
66. Smith G., Carey F.A., et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(14):9433-9438.
67. Min/+ mice. Cancer Research 2006, 66(17):8430-8438.
68. Solomon S.D., McMurray J.J.V., et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. New England Journal of Medicine 2005, 352(11):1071-1080.
69. Steinbach G., Lynch P.M., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. New England Journal of Medicine 2000, 342(26):1946-1952.
70. Sun F.X., Sasson A.R., et al. An ultra-metastatic model of human colon cancer in nude mice. Clinical and Experimental Metastasis 1999, 17(1):51-58.
71. Suraweera N., Haines J., et al. Genetic determinants modulate susceptibility to pregnancy-associated tumourigenesis in a recombinant line of Min mice. Human Molecular Genetics 2006, 15(23):3429-3435.
72. Takaku K., Oshima M., et al. Intestinal tumorigenesis in compound mutant mice of both Dpc4 (Smad4) and Apc genes. Cell 1998, 92(5):645-656.
73. Van Leeuwen I.M.M., Byrne H.M., et al. Crypt dynamics and colorectal cancer: advances in mathematical modelling. Cell Proliferation 2006, 39(3):157-181.
74. Min/+(Min) mouse with R-flurbiprofen. Life Sciences 2000, 66(8):745-753.
75. Williams K.J., Telfer B.A., et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. British Journal of Cancer 2002, 86(7):1157-1161.
76. Wood L.D., Parsons D.W., et al. The genomic landscapes of human breast and colorectal cancers. Science Signalling 2007, 318(5853):1108-1113.